Superbugs II: How should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?

Health Economics

Volumn 11, Issue 7, 2002, Pages 637-647

  Coast, Joanna ^a   Smith, Richard ^b   Karcher, Anne Marie ^c   Wilton, Paula ^b   Millar, Michael ^d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE TRANSMISSION; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; MEASUREMENT; MEDICAL RESEARCH; NONBIOLOGICAL MODEL; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES, EMERGING; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; EVALUATION STUDIES; EVIDENCE-BASED MEDICINE; HEALTH POLICY; HEALTH SERVICES RESEARCH; HUMANS; UNCERTAINTY;

EID: 0036799925     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.693     Document Type: Article

References (58)

1. Reacher MH, Shah A, Livermore DM et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. Br Med J 2000; 320: 213-216.
2. Davey PG, Bax RP, Newey J et al. Growth in the use of antibiotics in the community in England and Scotland in 198-93. Br Med J 1996; 312: 613.
3. Cox RA, Conquest C, Mallaghan C, Marples RR. A major outbreak of methicillin-resistant Staphylococcus aureus caused be a new phage-type (EMRSA-16). J Hosp Infect 1995; 29: 87-106.
4. Amyes SGB. The rise in bacterial resistance. Br Med J 2000; 320: 199-200.
5. Carbon C, Bax RP. Regulating the use of antibiotics in the community. Br Med J 1998; 317: 663-665.
6. Pringle M. Access to antibiotics: a case for a change in category. J Antimicrob Chemother 1995; 36: 577-579.
7. Reeves DS, Lewis DA. Over the counter anti-infectives - of benefit to whom? J Antimicrob Chemother 1995; 36: 579-583.
8. Hollis-Triantafillou J. Over the counter antibiotics. Br Med J 1996; 312: 644
9. Kubin CM. Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 1993; 118: 557-561.
10. Murray BE. Can antibiotic resistance be controlled? N Engl J Med 1994; 330(17): 1229-1230.
11. Levy J. Antibiotic resistance in Europe and the current use of antibiotics in severe pediatric infections. Scand J Infect Dis 1990; 73: 23-29.
12. Tomasz A. Multiple-antibiotic resistant pathogenic bacteria. A report on the Rockefeller University workshop. N Engl J Med 1994; 330(17): 1247-1251.
13. Williams JD. Antibiotic policy. Scand J Infect Dis 1986; 49: 175-181.
14. Standing Medical Advisory Committee Sub-Group on Antimicrobial Resistance. The Path of Least Resistance. Department of Health: London, 1998.
15. World Health Organisation. Overcoming Antimicrobial Resistance, WHO/CDS/2000.2. WHO: Geneva, 2000.
16. American Society for Microbiology. Report of the ASM task force on antibiotic resistance. Antimicrob Agents Chemother 1995; 10 (Suppl): 1-23.
17. Congress US. Impacts of antibiotic-resistant bacteria, OTA-H-629. US Government Printing Office: Washington DC, 1995.
18. Director General. The World Health Report 1996. Fighting Disease, Fostering Development. World Health Organisation: Geneva, 1996.
19. Hunt L. Perfect culture for a 'superbug'. The Independent 1996; 27 Feb (part 2): 7.
20. Garrett L. Mutating microbes. Independent on Sunday 1995; 17 Sept: 64-65.
21. Anon. Antibiotics: agents lose their cutting edge. Guardian Education 1998; 5 May: 10-11.
22. Hawkes N. Superbug in danger of winning war with hospital drugs. The Times 1995; April 4.
23. Horton R. The infected metropolis. Lancet 1996; 347: 134-135.
24. Laurance J. Bugs resistant to antibiotics on the increase. The Independent 1998; 24 July: 11.
25. Phelps CE. Bug/drug resistance. Sometimes less is more. Med Care 1989; 27: 194-203.
26. Evans RG. Strained mercy: the economics of Canadian health care. Butterworths: Toronto, 1984.
27. Brown G, Layton DF. Resistance economics: social cost and the evolution of antibiotic resistance. Environ Dev Econ 1996; 1: 349-355.
28. Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ 1996; 5: 217-226.
29. Coast J, Smith RD, Millar MR. An economic perspective on policy to reduce antimicrobial resistance. Soc Sci Med 1998; 46(1): 29-38.
30. Smith RD, Coast J. Controlling antimicrobial resistance: a proposed transferable permit market. Health Policy 1998; 43: 219-232.
31. Oates WE. Introduction. In Oates WE (ed). The Economics of the Environment. Edward Elgar: Aldershot, Hants, 1992; xiii-xv.
32. Neu HC. Antimicrobial chemotherapy, 1934-1994. Antimicrob Infect Dis Newslett 1994; 13: 1-8.
33. Magee JT, Pritchard EL, Fitzgerald KA, Dunstan FDJ, Howard AJ. Welsh Antibiotic Study Group. Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8. Br Med J 1999; 319: 1239-1240.
34. Spratt BG. Antibiotic resistance: counting the cost. Curr Biol 1996; 6: 1219-1221.
35. Chief Medical Officer, Chief Nursing Officer, Chief Pharmacist. Public Information Campaign on Antibiotic Resistance to be Launched in October. PL/CMO/99/3, PL/CNO/99/7, PL/CPHO/99/2. Department of Health: London, 1999.
36. Austin DJ, Anderson RM. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos Trans R Soc London 1999; 354: 721-738.
37. Public Health Laboratory Service. Reports from the Nosocomial Infection National Surveillance Scheme. Public Health Laboratory Service, 2000.
38. Verwaest C, Verhaegen J, Ferdinande P et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Crit Care Med 1997; 25: 63-71.
39. Quinio B, Albanese J, Bues-Charbitt M, Viviand X, Martin C. Selective decontamination of the digestive tract in multiple trauma patients. A prospective double-blind, randomized, placebo-controlled study. Chest 1996; 109: 765-772.
40. Larson EL. A causal link between handwashing and risk of infection? Examination of the evidence. Infect Control 1988; 9: 28-36.
41. Hedin G, Hambraeus A. Daily scrub with chlorhexidine reduces skin colonization by antibiotic-resistance Staphylococcus. J Hosp Infect 1993; 24: 47-61.
42. Haley RW, Culver DH, White JW et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 1985; 121: 182-205.
43. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus. A cost-benefit analysis in an intensive care unit. J Am Med Assoc 1999; 282: 1745-1751.
44. Rao N, Jacobs S, Joyce L. Cost-effective eradication of an outbreak of methicillin-resistant Staphylococcus aureus in a community teaching hospital. Infect Control Hosp Epidemiol 1988; 9: 255-260.
45. Zwar N, Wolk J, Gordon J, Sanson-Fisher R, Kehoe L. Influencing antibiotic prescribing in general practice: a trial of prescriber feedback and management guidelines. Fam Practice 1999; 16: 495-500.
46. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996; 124: 884-890.
47. Belongia EA, Schwartz B. Strategies for promoting judicious use of antibiotics by doctors and patients. Br Med J 1998; 317: 668-671.
48. Ashley DJB, Brindle MJ. Penicillin resistance in staphylococci isolated in a casualty department. J Clin Pathol 1960; 13: 336-338.
49. Krahn M, Gafni A. Discounting in the economics evaluation of health care interventions. Med Care 1993; 31: 403-418.
50. Broome J. Counting the Cost of Global Warming. White Horse Press: Cambridge, 1992.
51. Sugden R, Williams A. The Principles of Practical Cost-Benefit Analysis. Oxford University Press: Oxford, 1978.
52. Arrow KJ, Fisher AC. Environmental preservation, uncertainty and irreversibility. Q J Econ 1974; 88: 312-319.
53. Pearce DW, Turner RK. Economics of Natural Resources and the Environment. Harvester Wheatsheaf: London, 1990.
54. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dise 1987; 9(6): 1065-1078.
55. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159: 1127-1132.
56. Freeman AMI. The Measurement of Environmental and Resource Values. Theory and Methods. Resources for the Future: Washington DC, 1993.
57. Weisbrod BA. Collective-consumption services of individual-consumption goods. Q J Econ 1964; 78: 471-477.
58. Fishkin JS. Democracy and deliberation. New Directions for Democratic Reform. Yale University Press: London, 1991.